This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Other specified HIV disease conditions기타 명시된 병태

Contents and key points
ItemDetails
A. Classification codesICD-10: B23.8 (Other specified HIV disease conditions) | Special Copayment Reduction: V103 (severe intractable disease, 5 years)
B. SynonymsOther specified HIV-associated conditions; HIV-related conditions NEC (not elsewhere classified); HIV-related non-AIDS conditions
C. Adult onsetLikelihood of onset in adulthood: Very high — B23.8 is a residual code that classifies specified HIV-related conditions among those related to HIV infection that are not included in other codes of B20-B23.2 and B24. Various non-AIDS complications occurring in persons with HIV, such as kidney disease, cardiovascular disease, skin disease, and oral lesions, may be included.
1. HistoryThe category of non-AIDS complications related to HIV infection has expanded since the ART era. Kidney disease (HIVAN), cardiovascular disease (HIV-associated atherosclerosis), and oral lesions (hairy leukoplakia, oral candidiasis, etc.) are recognized as representative conditions included in B23.8. A comprehensive code for specified conditions not elsewhere classified in the ICD-10 B23 category.
2. CausesDirect effects of HIV (HIVAN, HIV cardiomyopathy). Chronic immune activation (accelerated cardiovascular disease, kidney damage). ART drug toxicity (nephrotoxicity: TDF; dyslipidemia: PI). HIV-associated chronic inflammation. Skin and oral lesions due to immunodeficiency.
3. GeneticsNot a hereditary disease. APOL1 gene variants (G1, G2): markedly increase the risk of HIVAN and HIV-associated kidney disease in persons with HIV of African descent. HLA-B*57:01: genetic predictor of abacavir hypersensitivity reaction (skin rash, systemic hypersensitivity reaction).
4. General epidemiologyHIVAN: occurs in 1-2% of African American patients with HIV; risk increases 15- to 50-fold in carriers of APOL1 G1/G2. HIV-associated cardiovascular disease: 1.5- to 2-fold increase compared with the general population. Oral lesions (oral candidiasis, hairy leukoplakia): 30-50% of patients with CD4 <200. HIV-associated kidney disease: about 3-5% of all.
5. PathophysiologyHIVAN: direct HIV infection of glomerular podocytes → glomerular collapse. Cardiovascular disease: chronic immune activation → vascular endothelial dysfunction → accelerated atherosclerosis. Oral lesions: immunodeficiency → proliferation of opportunistic microorganisms. ART metabolic toxicity: dyslipidemia → increased cardiovascular risk.
6. SymptomsHIVAN: proteinuria, edema, symptoms of renal failure. Cardiovascular: chest pain, dyspnea, symptoms of peripheral arterial disease. Oral lesions: oral pain, white patches (candida), white folds on the side of the mouth (hairy leukoplakia). HIV-associated kidney disease: edema, hematuria, hypertension.
7. SignsHIVAN: proteinuria >1 g/day, kidneys with increased echogenicity on ultrasound, rapid progression of renal failure. Cardiovascular: hyperlipidemia, hypertension, decreased ABI. Oral: candida (pseudomembranous), hairy leukoplakia (EBV-associated). TDF nephrotoxicity: decreased TmP/GFR, hypophosphatemia, Fanconi syndrome.
8. ScreeningHIVAN screening: urine protein/creatinine ratio (UPCR), eGFR measurement. Cardiovascular screening: fasting lipid panel, blood pressure, blood glucose. Oral examination: observe the oral mucosa at every visit. TDF nephrotoxicity: monitor serum creatinine, phosphate, and urine phosphate.
9. DiagnosisHIVAN: kidney biopsy (collapsing glomerulopathy pattern, HIV p24 antigen positive). Cardiovascular disease: Framingham/D:A:D risk scores. Hairy leukoplakia: characteristic clinical findings (white folds on the side of the mouth, EBV PCR positive, response to acyclovir treatment). Oral candidiasis: KOH smear, clinical findings.
10. TreatmentInitiation of ART (most effective for HIVAN and lesions related to immunodeficiency). HIVAN: ACE inhibitor/ARB, renal protection. In TDF nephrotoxicity, switch to TAF or abacavir. Oral candidiasis: fluconazole. Hairy leukoplakia: mostly resolves with ART alone. Cardiovascular: statins, blood pressure control, lifestyle improvement.
11. PrognosisHIVAN: without treatment, progresses to end-stage renal disease within 1-4 years. Progression can be suppressed with ART and ACE inhibitors. Cardiovascular: risk persists even after ART; statins reduce risk. Oral lesions: mostly improve or resolve after ART.
12. PreventionEarly HIV diagnosis and ART prevent HIVAN and immune-related lesions. Prevention of TDF nephrotoxicity: monitor renal function, prefer TAF. Cardiovascular prevention: smoking cessation, management of lipids, blood glucose, and blood pressure. Oral hygiene education, prevention of oral candidiasis (selective fluconazole prophylaxis when CD4 <200).
13. ReferencesIncludes 10 key references

1. History

ICD-10 B23.8 is "other specified HIV disease conditions," a residual code encompassing clinical conditions with a specified relationship to HIV infection that are not included in B20-B23.2 or B24.

In the early AIDS epidemic, opportunistic infections and AIDS-defining malignancies were the focus of clinical research. After the introduction of ART in the 1990s, the occurrence of AIDS-defining illnesses decreased and the survival of persons with HIV was extended dramatically, so various HIV-related complications other than AIDS-defining conditions emerged as new clinical challenges.

HIV-associated nephropathy (HIVAN) was first described by Rao et al. in 1984. It is a distinctive kidney disease that progresses rapidly to renal failure in African American persons with HIV, and is characterized histologically by a collapsing glomerulopathy pattern. Subsequently, in 2010, APOL1 gene variants (G1, G2) were found to be the main genetic predisposition for HIVAN.

The increase in HIV-associated cardiovascular disease has been reported in several cohort studies since the 2000s. The D:A:D study (Drug Abuser Death and Drug Abuse Cohort) showed that the incidence of coronary artery disease in persons with HIV is higher than in the general population, and that this is related to the metabolic adverse effects of ART drugs (especially PIs) and chronic immune activation accelerating atherosclerosis.

Oral mucosal lesions have been recognized since the early stage of HIV infection. Oral candidiasis was one of the diagnostic criteria of the pre-AIDS stage (ARC), and in the mid-1980s oral hairy leukoplakia was described as an EBV-associated complication of HIV. Oral hairy leukoplakia is a lesion that can be treated with acyclovir or ART, and is an important clinical indicator of immunosuppression.

In the current ART era, HIV infection is managed as a "chronic disease," and prevention and treatment of non-AIDS complications (kidney disease, cardiovascular disease, osteoporosis, neurocognitive disorders, liver disease, etc.) have become the core tasks of HIV clinical care. The B23.8 code is used to classify such varied, specified HIV-related conditions.

2. Causes

The causes of the other specified HIV-related conditions classified under B23.8 involve a combination of direct effects of HIV infection, chronic immune activation, ART drug toxicity, and opportunistic microbial infection.

Direct organ damage by HIV: HIV directly infects glomerular podocytes and renal tubular epithelial cells, causing HIV-associated nephropathy (HIVAN). HIV cardiomyopathy arises either from HIV directly infecting cardiomyocytes or from HIV proteins (gp120, Tat) disturbing cardiomyocyte function. HIV Tat increases oxidative stress in vascular endothelial cells, causing endothelial dysfunction.

Complications caused by chronic immune activation: Persistent immune activation causes vascular inflammation and accelerates atherosclerosis. Chronic activation of CD8+ T cells and monocytes promotes inflammatory responses in the vessel wall, raising the risk of coronary artery disease. Elevated IL-6, TNF-α, and CRP are independent indicators of cardiovascular disease risk. Chronic immune activation accelerates bone loss and osteoporosis.

ART drug toxicity: Tenofovir disoproxil fumarate (TDF): renal tubular toxicity, especially proximal tubular dysfunction (Fanconi syndrome) and decreased bone mineral density. Protease inhibitors (PI): cause insulin resistance, dyslipidemia, and visceral fat accumulation, raising metabolic syndrome and cardiovascular risk. Abacavir (ABC): some studies link it to increased cardiovascular disease risk (D:A:D study), but the mechanism remains controversial.

Proliferation of opportunistic pathogens due to immunodeficiency: Oral candidiasis: Candida albicans overgrows on the oral mucosa in the immunodeficient state. Oral hairy leukoplakia: EBV reactivates and proliferates in oral mucosal epithelial cells. HIV-associated HPV lesions (genital warts, precursor lesions of anorectal cancer): reduced ability to clear HPV due to CD4 decline.

3. Genetics

Specific genetic predispositions are involved in some of the HIV-related conditions in the B23.8 category.

APOL1 gene variants and HIVAN: The G1 (rs73885319, rs60910145) and G2 (rs71785313) variants of the APOL1 gene are common in populations of African origin, and originally had the advantage of conferring resistance to African sleeping sickness (Trypanosoma brucei gambiense). In persons with HIV carrying homozygous (G1/G1, G2/G2) or compound heterozygous (G1/G2) genotypes, the risk of HIVAN increases up to 29- to 89-fold compared with non-carriers. HIVAN develops in about 15-20% of African American persons with HIV who have the APOL1 high-risk genotype.

HLA-B*57:01 and abacavir hypersensitivity reaction: In HLA-B*57:01 carriers, severe hypersensitivity reactions (fever, rash, gastrointestinal symptoms, dyspnea, hypotension) occur when abacavir (ABC) is given. HLA-B*57:01 presents ABC metabolites as non-self, activating CD8+ T cells. Current guidelines mandate HLA-B*57:01 testing before giving ABC, and ABC is contraindicated if positive.

Polymorphisms related to cardiovascular disease: The APOE ε4 allele is associated with dyslipidemia and cardiovascular disease risk in persons with HIV. The severity of dyslipidemia caused by PI-based ART differs greatly according to APOE genotype. CYP2B6 gene polymorphisms affect the pharmacokinetics of efavirenz and are related to the occurrence of neuropsychiatric adverse effects and central nervous system abnormalities.

Genes related to osteoporosis: VDR (vitamin D receptor) gene polymorphisms are related to the risk of decreased bone mineral density in persons with HIV. RANKL/OPG gene polymorphisms may influence HIV-associated bone loss. TDF-associated decreased bone mineral density may interact with PHEX gene polymorphisms (regulation of phosphate metabolism).

4. General epidemiology

The epidemiology of the various HIV-related conditions included in B23.8 differs by disease.

HIV-associated kidney disease (HIVAN and non-HIVAN): HIVAN is the most frequent kidney disease in African American persons with HIV. Among untreated persons with HIV, HIVAN develops in about 20% of carriers of the APOL1 high-risk genotype. The incidence of HIVAN has decreased since ART, but it is still a leading cause of end-stage renal disease in African American patients in the US. TDF-associated nephrotoxicity (tubular damage) occurs in about 3-7% of patients using TDF, and the risk increases with underlying kidney disease or concurrent use of nephrotoxic drugs.

HIV-associated cardiovascular disease: In the D:A:D cohort study, the incidence of acute myocardial infarction (MI) in persons with HIV was about 1.5 to 2 times higher than in the general population. HIV infection itself (chronic immune activation) independently raises cardiovascular risk, and some ART drugs (abacavir, certain PIs) add further risk. HIV-associated cardiovascular risk interacts with traditional risk factors such as smoking, hyperlipidemia, hypertension, and diabetes.

Oral lesions: Oral candidiasis occurs in 30-50% of patients with CD4 <200/μL and was observed in 90% of patients with AIDS before ART. Oral hairy leukoplakia occurs mainly in the CD4 range of 100-300/μL and was observed in about 20-25% of persons with HIV before ART. The incidence of both lesions has decreased markedly since ART.

Osteoporosis and fractures: The prevalence of osteoporosis in persons with HIV is 3 to 7 times higher than in the general population. Bone mineral density decreases by 2-6% during the first 2 years after starting ART (especially regimens containing TDF and PIs). The fracture risk is about 30-40% higher than in the general population.

5. Pathophysiology

The pathophysiology of the main component conditions of B23.8 is summarized below.

Pathophysiology of HIVAN: HIV directly infects renal glomerular podocytes, proximal tubular epithelial cells, and mesangial cells. The HIV nef and vpr proteins induce cell cycle entry and apoptosis in podocytes, causing podocyte loss and collapsing glomerulopathy. APOL1 high-risk variants directly promote cell injury in podocytes, amplifying the nephrotoxic effect of HIV. As a result, collapsed glomeruli and hyperplastic endogenous cells appear as characteristic histologic findings.

Mechanism of accelerated cardiovascular disease: HIV-associated chronic immune activation → infiltration of the vessel wall by monocytes/macrophages → accelerated atherosclerosis. LPS (from bacterial translocation) → TLR4 stimulation → monocyte activation → increased oxidized LDL production → vascular endothelial damage. When CD4+ T cells decrease, vascular protective factors (IL-10, TGF-β) decrease → excessive vascular inflammation. PI-induced insulin resistance, increased triglycerides, and decreased HDL jointly raise atherosclerotic risk factors.

Mechanism of oral lesions: Oral candidiasis: decreased CD4+ T cells reduce the function of Th17 cells (key to anti-Candida defense) → increased adhesion and proliferation of Candida albicans on the mucosal epithelium. Oral hairy leukoplakia: HIV immunosuppression reactivates latent EBV infection in oral epithelium → EBV proliferation within epithelial cells → formation of white folds. HPV-associated lesions: decreased CD8+ T cells reduce the ability to clear HPV-infected cells → genital warts and anal intraepithelial neoplasia (AIN).

Mechanism of bone loss: HIV gp120 causes osteoclast activation and osteoblast suppression. Chronic immune activation → increased RANKL, decreased OPG → osteoclast hyperactivity → increased bone resorption. TDF: inhibition of renal tubular phosphate reabsorption → hypophosphatemia → secondary hyperparathyroidism → bone loss. PI: inhibition of vitamin D metabolism → vitamin D deficiency → bone loss.

6. Symptoms

The main clinical symptoms of each condition included in B23.8 are as follows.

Symptoms of HIVAN: Asymptomatic at first, but proteinuria (massive proteinuria, 3.5 g/day or more) is found on urinalysis. As it progresses, edema (ankles, lower extremities), fatigue, and anorexia appear. Malignant hypertension is atypical but occurs in some. Renal failure progresses rapidly (within months to 1 year in HIVAN), with oliguria and uremic symptoms. Nephrotic syndrome is common in HIVAN (proteinuria + hypoalbuminemia + edema).

Symptoms of cardiovascular disease: Coronary artery disease: chest pain (angina or acute MI), dyspnea. Peripheral arterial disease: leg pain on walking (intermittent claudication). Cerebrovascular disease: headache, transient ischemic attack (TIA), stroke symptoms. HIV-associated cardiomyopathy: dyspnea, edema, fatigue (heart failure symptoms). Most early increases in cardiovascular risk are asymptomatic and are found only by testing.

Symptoms of oral lesions: Oral candidiasis: white pseudomembrane in the mouth (can be scraped off), oral pain, taste disturbance, discomfort on swallowing. Oral hairy leukoplakia: longitudinal white folds or plaques on the side of the mouth (lateral tongue) (not removed by scraping), mostly asymptomatic but discomfort is possible. Aphthous oral ulcers: painful ulcers of the oral mucosa, difficulty eating.

Symptoms of osteoporosis and fractures: Early osteoporosis is asymptomatic, but T-score <-2.5 on DEXA. With a fracture, pain and functional limitation. Vertebral compression fracture: back pain, height loss. Hip fracture: hip pain, gait disturbance (increased risk of falls in older persons with HIV).

7. Signs

Signs of HIVAN: Urinalysis: massive proteinuria (nephrotic range, ≥3.5 g/day), microscopic hematuria (not uncommon). Elevated serum creatinine, decreased eGFR. Decreased serum albumin (hypoalbuminemia), elevated serum cholesterol (nephrotic response). Renal ultrasound: normal or increased echogenicity, normal kidney size (a characteristic feature is that the kidneys do not shrink despite rapid progression). Kidney biopsy: collapsing glomerulopathy, tubular dysplasia, interstitial fibrosis and edema.

Cardiovascular signs: Elevated blood pressure, pulse abnormalities. ECG: ST changes, arrhythmia. Echocardiography: decreased left ventricular function, cardiomyopathy. Increased carotid intima-media thickness (IMT), atherosclerotic plaque. Lipid tests: increased LDL, decreased HDL, increased triglycerides.

Oral examination findings: Oral candidiasis: pseudomembranous (white cheese-like, removable by scraping, mucosal redness), atrophic (smooth red mucosa), erythematous. Oral hairy leukoplakia: longitudinal white streaks or plaques on the lateral tongue, EBV EBER ISH positive. Oral KS (Kaposi sarcoma): purple plaques or nodules (predominantly hard palate and gums). Oral aphthous ulcers: painful ulcers <1 cm in diameter.

Bone mineral density testing: DEXA: lumbar spine or hip T-score <-1 (osteopenia) or <-2.5 (osteoporosis). Decreased serum vitamin D, elevated PTH (secondary hyperparathyroidism). Decreased serum phosphate (in TDF renal tubular toxicity).

8. Screening

Regular screening tests are performed for the various HIV-related conditions falling under B23.8.

Kidney function screening: In all persons with HIV, measure serum creatinine, eGFR, and urine protein/creatinine ratio (UPCR) every 6-12 months. In patients using TDF, monitor kidney function every 3 months. UPCR >0.2 (or proteinuria >200 mg/g) is abnormal. In African American patients with the APOL1 high-risk genotype, consider HIVAN first when proteinuria develops.

Cardiovascular risk screening: Before starting ART and every 12 months during ART: fasting lipid panel (total cholesterol, LDL, HDL, triglycerides), fasting blood glucose (diabetes screening), blood pressure measurement. Assess 10-year cardiovascular risk with the D:A:D cardiovascular risk score or the Framingham score. In high-risk patients (10-year risk >20%), consider carotid ultrasound and coronary artery calcium score CT.

Oral screening: At every outpatient visit, observe the oral mucosa to screen for candidiasis, hairy leukoplakia, KS, and oral ulcers. Screening for oral candidiasis is more important in patients with CD4 <200/μL.

Bone mineral density screening: Perform DEXA in men aged 50 or older with HIV, or in postmenopausal women with HIV. In patients on TDF-based ART, measure DEXA within 1-2 years after starting ART. Perform at a younger age if risk factors are present (smoking, low body weight, long-term steroid use, vitamin D deficiency).

9. Diagnosis

The diagnostic criteria for each main condition in the B23.8 classification are summarized as follows.

Diagnosis of HIVAN: Clinical diagnostic criteria: HIV infection + proteinuria (UPCR >1.0 or 24-hour proteinuria >1 g) + decreased eGFR. Kidney biopsy is the confirmatory method. Histologic findings: collapsing focal segmental glomerulosclerosis, tubular dysplasia (microcystic tubular dilatation), interstitial edema and infiltration. Immunofluorescence: nonspecific deposition of IgM and C3. Electron microscopy: tubuloreticular inclusions in endothelial cells.

Assessment of HIV-associated cardiovascular risk: D:A:D risk score: a comprehensive risk calculation tool including age, sex, smoking, diabetes, systolic blood pressure, TC/HDL ratio, CDC stage, abacavir use, and duration of ART. Diagnosis of coronary artery disease: clinical symptoms + ECG + echocardiography + coronary angiography (if needed). Peripheral arterial disease: ankle-brachial index (ABI) <0.9.

Diagnosis of oral hairy leukoplakia: Characteristic clinical findings (white longitudinal folds on the side of the mouth, not removed by scraping) + confirmation of EBV infection (EBV EBER in situ hybridization positive). Trial of acyclovir treatment (2 weeks): resolution of the lesion supports the diagnosis. Confirmation of positive EBV DNA PCR in epithelial cells.

Diagnosis of osteoporosis: DEXA: lumbar spine or hip T-score ≤-2.5 (osteoporosis), -1.0 to -2.5 (osteopenia). Compare bone mineral density relative to age using the Z-score. Fracture risk assessment: FRAX score (WHO fracture risk assessment tool) with added risk related to HIV infection.

10. Treatment

Treatment of the main conditions in B23.8 is as follows.

Treatment of HIVAN: Immediate initiation of ART is the most effective treatment for suppressing HIVAN progression. Kidney function can stabilize or recover with HIV RNA suppression by ART. Renin-angiotensin system inhibitors (ACE inhibitor or ARB): reduce proteinuria and protect the kidney. Spironolactone or empagliflozin: additional renal protection. In patients on TDF-based ART who develop HIVAN or TDF nephrotoxicity, adjust ART to TAF or abacavir (after confirming HLA-B*57:01 negativity). In end-stage renal failure, consider dialysis or kidney transplantation (HIV infection is not a contraindication to transplantation).

Cardiovascular risk management: Control of traditional cardiovascular risk factors: hypertension (target <130/80 mmHg), lipids (use of statins), diabetes, smoking cessation. Statins: atorvastatin or rosuvastatin have fewer ART drug interactions. In patients at high cardiovascular risk, consider substitution with TAF/TDF in view of the cardiovascular risk of abacavir. Antiplatelet agents (aspirin): standard use for secondary prevention (after myocardial infarction or stroke).

Treatment of oral lesions: Oral candidiasis (pseudomembranous): fluconazole 200 mg on the first day, then 100-200 mg/day for 7-14 days. Topical treatment (clotrimazole troches, nystatin suspension) can also be used for mild cases. Prevention of recurrent candidiasis: fluconazole 200 mg/week (in severe immunodeficiency with CD4 <50/μL). Oral hairy leukoplakia: mostly resolves after starting ART. If discomfort is severe, acyclovir 400 mg 5 times daily for 7-14 days. Aphthous ulcers: topical corticosteroid ointment; in severe cases, thalidomide (can be used for severe aphthous ulcers in persons with HIV).

Treatment of osteoporosis: Correction of vitamin D deficiency (vitamin D₃ 1,000-2,000 IU/day) + calcium supplementation (1,200 mg/day). Confirmed osteoporosis (T-score ≤-2.5) or osteopenia with high fracture risk: bisphosphonate (alendronate 70 mg/week or risedronate 35 mg/week). Patients with TDF-associated decreased bone mineral density: switch to TAF or abacavir. Resistance exercise and aerobic exercise are recommended.

11. Prognosis

Prognosis of HIVAN: In the pre-ART era, the median survival of patients with HIVAN was 1-4 months until progression to end-stage renal disease. Since the introduction of ART, HIVAN progression has been greatly delayed, but rapid progression of renal failure is still observed when ART is started late or fails. Combined treatment with ART + ACE inhibitor has greatly improved 5-year kidney function preservation. The 5-year survival rate of persons with HIV after kidney transplantation is reported to be similar to that of persons without HIV.

Cardiovascular prognosis: Mortality after acute MI in persons with HIV is slightly higher than in the general population, but has improved considerably in patients on ART. Statin treatment reduces the risk of cardiovascular events in persons with HIV by 20-30% (REPRIEVE study). Chronic immune activation persists despite ART, so cardiovascular risk does not return completely to normal.

Prognosis of oral lesions: In patients who respond to ART, oral candidiasis and hairy leukoplakia mostly improve or resolve. Recurrent candidiasis may persist if CD4 recovery is poor or azole resistance develops. Oral hairy leukoplakia itself does not become malignant, but serves as a persistent indicator of immunosuppression.

Prognosis of osteoporosis: In patients on ART, bone mineral density generally decreases during the first 2 years and then stabilizes. When switching to TAF, TDF-associated decreases in bone mineral density tend to reverse. Bisphosphonate treatment reduces fracture risk by about 30-50%.

12. Prevention

Early HIV diagnosis and ART: Early HIV diagnosis and immediate ART initiation prevent HIVAN, oral lesions, and complications related to immunosuppression. The higher the CD4 level at which treatment is started, the less organ damage (kidney, cardiovascular) from chronic immune activation occurs.

ART selection and minimizing toxicity: Prevent abacavir hypersensitivity reaction through HLA-B*57:01 testing. Prefer TAF in patients at risk of TDF nephrotoxicity. In patients at high cardiovascular risk, prefer ART with fewer cardiovascular adverse effects (INSTIs + NRTI). When using PIs that cause dyslipidemia, consider regular lipid monitoring and statin use.

Correction of cardiovascular risk factors: Smoking cessation counseling and support (the smoking rate of persons with HIV is 3 times that of the general population). Regular measurement and control of blood pressure, lipids, and blood glucose. Prevent metabolic syndrome with aerobic exercise and diet control. Low-dose aspirin in high-risk patients (whether for primary prevention is an individualized decision).

Oral hygiene and bone health: Early detection of oral lesions through regular oral examination and dental visits. Prevent candidiasis with oral hygiene education (tooth brushing, mouthwash). Adequate vitamin D intake (sun exposure, supplements). Reduce fracture risk with resistance exercise and fall-prevention education. Minimize bone loss risk factors such as smoking, alcohol, and long-term steroid use.

13. References

  1. Rao TK, Fillippone EJ, Nicastri AD, et al. Associated focal and segmental glomerulosclerosis in the acquired immunodeficiency syndrome. N Engl J Med. 1984;310(11):669-673. PMID: 6363936
  2. Kopp JB, Nelson GW, Sampath K, et al. APOL1 genetic variants in focal segmental glomerulosclerosis and HIV-associated nephropathy. J Am Soc Nephrol. 2011;22(11):2129-2137. PMID: 21997396
  3. Friis-Møller N, Reiss P, Sabin CA, et al. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med. 2007;356(17):1723-1735. PMID: 17460226
  4. Currier JS, Lundgren JD, Carr A, et al. Epidemiological evidence for cardiovascular disease in HIV-infected patients and relationship to highly active antiretroviral therapy. Circulation. 2008;118(2):e29-35. PMID: 18591429
  5. Greenspan D, Greenspan JS, Hearst NG, et al. Relation of oral hairy leukoplakia to infection with the human immunodeficiency virus and the risk of developing AIDS. J Infect Dis. 1987;155(3):475-481. PMID: 3805323
  6. Pappas PG, Kauffman CA, Andes DR, et al. Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. Clin Infect Dis. 2016;62(4):e1-50. PMID: 26679628
  7. Brown TT, Qaqish RB. Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review. AIDS. 2006;20(17):2165-2174. PMID: 17086056
  8. Lundgren JD, Borges AH, Neaton JD. Serious non-AIDS conditions in HIV: benefit of early versus deferred ART. J Infect. 2017;74(Suppl 1):S100-S107. PMID: 28365306
  9. Carr A, Samaras K, Burton S, et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS. 1998;12(7):F51-F58. PMID: 9619798
  10. Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359(21):2195-2207. PMID: 18997196